Yarrow Bioscience (YARW) Net Equity Issued and Repurchased (2017 - 2023)

Yarrow Bioscience (YARW) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $156000.0 in Q1 2023.

• Quarterly Net Equity Issued and Repurchased fell 89.98% year-over-year to $156000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $156000.0 (down 26.07% YoY) and the FY2023 annual result came in at $156000.0, down 26.07% from the prior year.
• Net Equity Issued and Repurchased climbed to $156000.0 in Q1 2023, from -$1.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $73.1 million in Q1 2021 to a low of -$76.0 million in Q4 2021.
• A 5-year average of $6.3 million and a median of $2.1 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2019 — Net Equity Issued and Repurchased plunged 7841.18% — and 2020, when it surged 2138.22%.
• Tracing YARW's Net Equity Issued and Repurchased over 5 years: stood at $13.7 million in 2019, then slumped by 41.72% to $8.0 million in 2020, then slumped by 1050.96% to -$76.0 million in 2021, then surged by 98.34% to -$1.3 million in 2022, then soared by 112.38% to $156000.0 in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $156000.0 (Q1 2023), -$1.3 million (Q4 2022), and -$86000.0 (Q2 2022), per Business Quant data.